Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.

ABSTRACT: The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants seriously threatens the efficacy of current coronavirus disease 2019 (COVID-19) vaccines. Therefore, there is an urgent need to develop next-generation vaccine platforms capable of counteracting current and prospective viral variants. In this study, we employed synthetic biology technology to develop self-adjuvant-effect biomimetic nanovaccines with broad-spectrum capabilities for the prevention of SARS-CoV-2 infection. The biomimetic nanovaccines prepared by loading the SARS-CoV-2 RBD protein into dendritic mesoporous organosilicon nanoparticles (DMOSN) significantly promote the recruitment of dendritic cells (DCs) to secondary lymphoid organs, thereby initiating antibody-dependent humoral immune respon

SUBMITTER: Wang W 

PROVIDER: S-EPMC12645919 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature